Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 7/20 | 0.55 |
| ▸ | TTBK1 | Q5TCY1 | 5/20 | 0.51 |
| ▸ | TTBK2 | Q6IQ55 | 5/20 | 0.51 |
| ▸ | KDR | P35968 | 3/20 | 0.51 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3703169 | 0.85 | TTBK1 (0.59) | TTBK1TTBK2KDRENPP3MAPT | |
| SCHEMBL3703048 | 0.84 | KDR (0.50) | KDRENPP3LMNAMAPTGAA | |
| SCHEMBL2966793 | 0.81 | KDR (0.51) | KDRENPP3LMNAMAPTGAA | |
| SCHEMBL15663352 | 0.81 | KDR (0.50) | TTBK1TTBK2KDRENPP3LMNA | |
| SCHEMBL15663382 | 0.80 | MAPT (0.54) | KDRENPP3LMNAMAPT | |
| SCHEMBL2209315 | 0.80 | MAPT (0.54) | KDRENPP3LMNAMAPT | |
| SCHEMBL2210774 | 0.80 | AURKA (0.49) | KDRENPP3LMNAMAPTGAA | |
| SCHEMBL2209159 | 0.80 | KDR (0.50) | METKDRENPP3LMNAMAPT | |
| SCHEMBL3702833 | 0.80 | KDR (0.50) | KDRENPP3LMNAMAPTGAA | |
| SCHEMBL2204419 | 0.79 | KDR (0.49) | KDRENPP3LMNAMAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122847-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC. (US) | 2012-05-17 | — | — | US | claimed |
| EP-2137177-B1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC (US) | 2014-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122847-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AURKC, AURKA, CDK1 | MET 567/4885TTBK1 101/4885TTBK2 175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.